布地奈德福莫特罗联合噻托溴铵治疗慢性阻塞性肺疾病的效果和安全性分析

摘要
图/表
参考文献(16)
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨布地奈德福莫特罗联合噻托溴铵治疗慢性阻塞性肺疾病（COPD）的效果和安全性。方法选取2017年4月～2018年4月我院收治的117 例COPD 患者作为研究对象，采用随机数字表法将其分为参照组（n=59）和实验组（n=58）。参照组采用布地奈德福莫特罗吸入剂治疗，实验组则采用布地奈德福莫特罗吸入剂和噻托溴铵干粉胶囊联合治疗。观察两组在治疗前后的1 s 用力呼气容积（FEV1）、1 s 用力呼气容积/用力肺活量比值（FEV1/FVC）、FEV1 预计百分比（FEV1%）以及最大呼气流速（PEF）的改善情况，并观察临床症状改善情况和分析不良反应发生情况。结果治疗前，两组的FEV1、FEV1/FVC、FEV1%以及PEF 等肺功能指标比较，差异无统计学意义（P＞0.05）。治疗后，两组的各项肺功能指标均有不同程度的提高（P<0.05），且实验组的各项肺功能指标高于参照组，差异有统计学意义（P<0.05）。两组治疗前的圣乔治呼吸问卷（SGRQ）评分比较，差异无统计学意义（P＞0.05）。治疗后实验组的SGRQ 评分低于参照组，差异有统计学意义（P<0.05）。实验组和参照组治疗的不良反应总发生率分别为15.52%、11.86%，差异无统计学意义（P＞0.05）。结论布地奈德福莫特罗联合噻托溴铵治疗COPD，能提高临床效果，有效改善患者的肺功能指标，且安全性良好，值得临床推广。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	曾立胜

关键词 ：慢性阻塞性肺疾病, 布地奈德福莫特罗, 噻托溴铵, 肺功能

Abstract：Objective To investigate the effect and safety of Budesonide Formoterol combined with Tiotropium Bromide in the treatment of chronic obstructive pulmonary disease (COPD).Methods A total of 117 patients with COPD admitted in our hospital from April 2017 to April 2018 were selected as study objects.They were divided into control group(n=59) and experimental group (n=58) according to random number table method.The patients in the control group were treated with Budesonide Formoterol Inhalation, the patients in the experimental group were treated with Budesonide Formoterol Inhalation and Tiotropium Bromide Dry Powder Capsules.The improvement of forced expiratory volume (FEV1), forced expiratory volume/forced vital capacity ratio (FEV1/FVC), predicted percentage of FEV1 (FEV1%)and maximal expiratory flow (PEF) were observed before and after treatment.And the improvement of clinical symptoms and the adverse reactions were observed.Results There was no significant difference in FEV1, FEV1/FVC, FEV1% and PEF between the two groups before treatment(P＞0.05).After treatment, the pulmonary function indexes of the two groups were improved to some extent (P<0.05), and the pulmonary function indexes of the experimental group were higher than those of the control group (P<0.05).There was no significant difference in (SGRQ) score of St George′s respiratory questionnaire between the two groups before treatment (P＞0.05).The SGRQ score of the experimental group was significantly lower than that of the control group (P<0.05).The total incidence of adverse reactions in the experimental group and the control group were 15.52 and 11.86, respectively.There was no significant difference between the two groups(P＞0.05).Conclusion Budesonide Formoterol combined with Tiotropium Bromide in the treatment of COPD, can improve the clinical effect, improve the pulmonary function more effectively, and is safe and worthy of clinical promotion.

Key words： Chronic obstructive pulmonary disease;Budesonide Formoterol Tiotropium Bromide Pulmonary function

作者简介: 曾立胜（1974-），男，汉族，广东惠州人，主治医师，主要从事内科疾病研究

引用本文:

曾立胜. 布地奈德福莫特罗联合噻托溴铵治疗慢性阻塞性肺疾病的效果和安全性分析[J]. 中国当代医药, 2019, 26(15): 78-80.
ZENG Li-sheng. Effect and safety of Budesonide Formoterol combined with Tiotropium Bromide in the treatment of chronic obstructive pulmonary disease. 中国当代医药, 2019, 26(15): 78-80.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2019/V26/I15/78